Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC
MADRID -- Treatment with cemiplimab (Libtayo) followed by surgery showed encouraging survival…
Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPC
MADRID -- Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC)…
New Options Challenge Standard Treatments in EGFR-Mutant NSCLC
MADRID -- Two positive phase III trials involving amivantamab (Rybrevant)-based regimens introduced…
ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer
MADRID -- Disease-free survival (DFS) in resectable ALK-positive non-small cell lung cancer…
Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers
MADRID -- Treatment with an investigational TROP2-directed antibody-drug conjugate (ADC) significantly improved…
Randomized Trial Backs HIF-2a Inhibition in Advanced RCC
MADRID -- Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg)…
More Data Support Adding Immunotherapy to Chemo in Advanced Endometrial Cancer
MADRID -- Patients with advanced endometrial cancer had less disease progression and…
Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer
MADRID -- Treatment with tisotumab vedotin (Tivdak) significantly extended overall survival (OS)…
Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer
MADRID -- The combination of a KRAS G12C inhibitor and an EGFR…
New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions
MADRID -- Amivantamab (Rybrevant) confirmed its clinical benefit in advanced non-small cell…
